Project Caldera
A rare opportunity exists to purchase the business and assets of a biotechnology company engaged in the development of its antibiotic platform technology, designed to serve as a new generation of antibiotics to combat antibacterial resistance.
The Company has attracted circa £30m of investment and support from global life science charities over the last two decades, to enable the continued development of its technology.
The Company’s technology involves using engineered bacterial viruses, or phages, to deliver a unique antibacterial protein to target bacteria, and is protected by eight patent families in key commercial territories internationally.
The Company’s lead product in development within this technology platform, which has already achieved proof of concept, serves as a potential solution to one of pathogens listed by The WHO as urgently requiring new antibiotics; ventilator associated pneumonia.
Asset Overview
- Eight patent families with international coverage in key commercial territories
- Critical organisational knowledge including R&D and clinical trial data & reports
- Lab equipment of varying age and condition
- Samples in relation to R&D output
- Stock in relation to the Company’s ventilator associated pneumonia product
Interested parties are requested to specifically deal and formally register their interest with Andrew Smith at SIA Group, who are acting as Agents on behalf of the Company.
It is intended that a sale will be executed at the earliest opportunity and offers or expressions of interest must be registered by no later than Noon, Monday 29th January 2024. We reserve the right to set a deadline for Best and Final offers to parties having offered or registered interest by this deadline. Access to the data room can be provided after executing an NDA.
are registered trademarks of SIA Group Asset Ingenuity Limited